Futibatinib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 113 publications
Phase 2 Study of Futibatinib in Combination with Pembrolizumab in Patients with FGF19 expressing Advanced Hepatocellular Carcinoma.
Journal: The oncologist
Published: June 11, 2026
FGFR2 Fusion Gene-Positive Solid Tumors
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: June 04, 2026
Isolation, structural elucidation and cytotoxicity evaluation of novel degradation impurities of futibatinib.
Journal: Journal of pharmaceutical and biomedical analysis
Published: June 01, 2026
Leveraging Healthy Volunteers for Anticancer Drug Clinical Pharmacology Studies: A Review Article Featuring Futibatinib as an Example.
Journal: Clinical and translational science
Published: May 22, 2026
The evolving role of futibatinib for advanced cholangiocarcinoma.
Journal: Expert review of gastroenterology & hepatology
Published: March 23, 2026
Pharmacovigilance analysis of the FGFR inhibitor futibatinib using the FDA adverse event reporting system (FAERS) database.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: March 21, 2026
Management of Nail Toxicities From Fibroblast Growth Factor Receptor Inhibitors.
Journal: Journal of drugs in dermatology : JDD
Published: March 04, 2026
Ocular Safety Signals of Fibroblast Growth Factor Receptor Inhibitors in Post-Marketing Surveillance.
Journal: American journal of ophthalmology
Published: February 16, 2026
Ocular Safety Signals of Fibroblast Growth Factor Receptor Inhibitors in Postmarketing Surveillance.
Ocular Safety Signals of Fibroblast Growth Factor Receptor Inhibitors in Postmarketing Surveillance.
Journal: American journal of ophthalmology
Published: February 16, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.
Journal: The Journal of clinical investigation
Published: February 12, 2026
Systemic therapy of biliary tract cancer: The road to personalised strategies.
Journal: Journal of hepatology
Published: February 04, 2026
Electroanalytical method development for the receptor tyrosine kinase inhibitor lenvatinib using a Ti3C2Tx-MXene based molecularly imprinted polymer modified carbon electrode.
Journal: Analytical and bioanalytical chemistry
Published: January 29, 2026
Last Updated: 09/26/2026